Three years ago, OpenEvidence was an idea sketched out by a former hedge-fund quant and a machine-learning researcher who thought doctors deserved a search engine built only for them. In January 2026, that idea closed a $250 million Series D round that doubled the Miami-based company’s valuation to $12 billion — up from just $1 billion a year earlier. For an industry that has spent decades watching software vendors overpromise and underdeliver at the bedside, the speed of that climb has become impossible to ignore.
From Kensho to the Clinic
OpenEvidence was founded in 2022 by Daniel Nadler, who previously co-founded the financial-analytics firm Kensho Technologies, and AI researcher Zachary Ziegler. The pairing is notable: Nadler had already built and sold one AI company to a giant institution — S&P Global acquired Kensho in 2018 — before turning his attention to medicine. The product the two built is, in essence, a clinical chatbot that draws on peer-reviewed medical literature to answer questions physicians pose at the point of care, whether they’re double-checking a drug interaction or working through a differential diagnosis between patients.
A Tool Doctors Say They Actually Use
What separates OpenEvidence from the long list of AI health startups that never made it past a pilot program is claimed adoption. Nadler says OpenEvidence is now the most widely used AI platform among doctors in the United States, with more than 40% of U.S. physicians using the tool. The company said it crossed $100 million in annualized revenue in January 2026, the same month as its funding announcement — a milestone that, if it holds, would mark unusually fast monetization for a clinical software product aimed at individual physicians rather than hospital procurement committees.
The Valuation Curve Keeps Bending Upward
The numbers tell a story of compounding investor enthusiasm. OpenEvidence was valued at roughly $1 billion a year before its January 2026 round, at $3.5 billion in July 2025, and then at $12 billion just months later. More recently in 2026, the company was reportedly in talks to raise another $200 million at a $20 billion valuation — nearly six times its mid-2025 mark. Few health-tech companies, let alone one built around a single chatbot interface, have seen valuation growth of that magnitude in such a compressed window.
Displacing an Incumbent, or Just Supplementing It?
For two decades, UpToDate has been the default reference tool many physicians reach for during a shift — a curated, editorially reviewed database rather than a generative AI system. OpenEvidence’s pitch is speed and conversational ease: instead of navigating a reference article, a doctor can ask a direct clinical question and get a synthesized answer sourced from the literature. That convenience is precisely what worries some clinicians and hospital administrators, who point to the well-documented risk of AI systems generating plausible-sounding but incorrect information, and to unresolved questions about liability if a physician acts on a flawed AI-generated answer. Proponents counter that OpenEvidence is designed to cite its underlying literature transparently, letting physicians verify sourcing themselves rather than trusting the model blindly — a meaningfully different posture than a general-purpose consumer chatbot.
What the Money Signals About AI in Medicine
OpenEvidence’s trajectory is also a proxy for a broader boom in AI-healthcare investment, where venture money is increasingly chasing tools built for the point of care rather than back-office administrative software. A jump from $1 billion to a potential $20 billion valuation in roughly a year reflects investor conviction that physician-facing AI has found real, recurring demand — not just curiosity clicks. Whether that conviction survives contact with reimbursement realities, malpractice case law, and competition from well-funded rivals building similar tools is the open question hanging over the next round.
What Comes Next
If OpenEvidence closes a raise at a $20 billion valuation, it will invite closer scrutiny of how such a young company justifies pricing on par with established health-tech incumbents. Regulators and hospital systems will also be watching adoption data more closely: a claim of 40% physician usage, if independently verified, would represent one of the fastest penetration rates for any clinical software tool in recent memory. For now, OpenEvidence’s climb stands as the clearest signal yet that investors believe AI chat interfaces, not just diagnostic algorithms, are becoming durable fixtures of clinical practice.
